APO Research
Talk to an analyst

APO RESEARCH · REPORT

KRAS Inhibitor

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

Selected research

Industry Growth & Trends

Global KRAS Inhibitor Industry Growth and Trends Forecast to 2032

24 December 202591 pages

Choose your research edition.

Industry ResearchKRAS Inhibitor Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal KRAS Inhibitor Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal KRAS Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KRAS Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal KRAS Inhibitor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

KRAS inhibitors are direct, targeted anticancer agents—almost all of them low-molecular-weight small molecules—that bind oncogenic KRAS proteins and prevent them from propagating downstream signaling through the RAF–MEK–ERK and PI3K–AKT pathways. In contemporary usage the term refers to drugs that physically engage mutant KRAS itself, most commonly hotspot alleles such as KRAS G12C and increasingly G12D or multi-mutant variants, rather than to upstream or downstream pathway blockers such as EGFR, MET, MEK or ERK inhibitors that modulate the same signaling network indirectly. In practice, current approved agents are allele-selective covalent inhibitors that recognize the cysteine introduced by the G12C mutation, trap KRAS in its inactive GDP-bound conformation, and thereby attenuate the chronic proliferative and survival signaling that characterizes KRAS-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors.

From a historical perspective KRAS inhibition represents the end of a four-decade “undruggable” saga. The RAS oncogenes HRAS and KRAS were among the first human cancer genes identified in the early 1980s, and activating RAS mutations are now known to drive roughly 20–30% of all human cancers, with KRAS the most frequently mutated isoform and almost universal in pancreatic ductal adenocarcinoma (PDAC). Despite intense medicinal-chemistry efforts, the small, smooth GTP-binding surface of KRAS was long thought to lack a druggable pocket. The field pivoted in 2013 when Shokat and colleagues described a previously unappreciated “switch II” allosteric pocket adjacent to the GTP-binding site that could be targeted by electrophilic fragments to form covalent adducts with cysteine at position 12 in KRAS G12C, opening the door to conformationally selective covalent inhibitors. This discovery set off an intense global race that, after nearly 40 years of negative experience, produced the first clinically successful KRAS-targeted drugs. Before 2021 there were no approved KRAS inhibitors and essentially no commercial revenue attributable to direct KRAS blockade; all treatment of KRAS-mutant tumors relied on cytotoxic regimens, immune checkpoint blockade, or pathway-level agents such as EGFR or MEK inhibitors.

The global KRAS inhibitor market is moving rapidly from an early-launch niche to a scaled targeted-oncology class. Based on APO Research’s estimates, global sales are expected to reach approximately US$0.49 billion in 2024 and grow to around US$3.18 billion by 2032, implying a strong CAGR of about 23–24% over 2025–2032. Growth is volume-driven rather than price-driven: worldwide demand is projected to increase from roughly 8.6 million to more than 78 million 120-mg-equivalent tablets over the same period, while global average net ex-factory prices gradually decline from the high-US$50s per tablet at launch to the low-US$40s by the early 2030s.

Read the full market overview

The market today is highly concentrated in a small number of tumour types and regions. Non-small-cell lung cancer (NSCLC) already accounts for the majority of KRAS inhibitor use, with colorectal cancer forming the second pillar and pancreatic plus other solid tumours contributing a small but fast-growing tail. North America remains the commercial centre of gravity, supported by high testing penetration, rapid reimbursement and comparatively high net prices. Europe scales later and at lower price points but still builds a meaningful second revenue pillar. Asia Pacific is the fastest-growing region: from a negligible base in 2021–2023, volumes expand sharply from 2024 onwards as Japan, South Korea, Australia and, critically, mainland China approve and commercialise KRAS G12C inhibitors. Because domestic products in China are priced materially below US and EU benchmarks, China’s late but rapid entry both reshapes the regional volume mix and pulls down Asia-Pacific average prices.

Competitive intensity is expected to increase as additional first-generation KRAS G12C inhibitors and next-generation molecules targeting other KRAS alleles enter the market. Amgen, Bristol Myers Squibb/Mirati, Innovent Biologics/GenFleet Therapeutics and Jacobio Pharma/Shanghai Allist Pharmaceuticals currently anchor the class, with other multinational and Chinese manufacturers developing follow-on assets. In 2024, the three largest vendors together account for well over 99% of global KRAS inhibitor revenue, but this concentration will moderate as new entrants launch, combination strategies proliferate and regional players consolidate positions in China and other emerging markets.

Report Scope

This report provides a structured, data-driven view of the global KRAS Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The KRAS Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (k bottles) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global KRAS Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to KRAS Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global KRAS Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

KRAS Inhibitor Market by Company

Amgen

InventisBio/Chia Tai Tianqing Pharmaceutical

Bristol Myers Squibb/Mirati

Innovent Biologics/GenFleet Therapeutics

Jacobio Pharma/Shanghai Allist Pharmaceuticals

KRAS Inhibitor Segment by Type

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Others

KRAS Inhibitor Segment by Application

Clinic Laboratories

Hospitals

Cancer Diagnostic Centres

Others

KRAS Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Lung Cancer Table 2. Major Company of Colorectal Cancer Table 3. Major Company of Pancreatic Cancer Table 4. Major Company of Others Table 5. Global KRAS Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 7. Global KRAS Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 8. Global KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 9. Global KRAS Inhibitor Sales Market Share in Value by Type (2021-2026) Table 10. Global KRAS Inhibitor Price by Type (2021-2026) & (USD/bottle) Table 11. Global KRAS Inhibitor Sales by Type (2027-2032) & (k bottles) Table 12. Global KRAS Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 13. Global KRAS Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 14. Global KRAS Inhibitor Sales Market Share in Value by Type (2027-2032) Table 15. Global KRAS Inhibitor Price by Type (2027-2032) & (USD/bottle) Table 16. North America KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 17. North America KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 18. Europe KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 19. Europe KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 21. Asia-Pacific KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 23. Latin America KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa KRAS Inhibitor Sales by Type (2021-2026) & (k bottles) Table 25. Middle East and Africa KRAS Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 26. KRAS Inhibitor Industry Trends Table 27. KRAS Inhibitor Industry Drivers Table 28. KRAS Inhibitor Industry Opportunities and Challenges Table 29. KRAS Inhibitor Industry Restraints Table 30. Global KRAS Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global KRAS Inhibitor Revenue Market Share by Company (2021-2026) Table 32. Global KRAS Inhibitor Sales by Company (2021-2026) & (k bottles) Table 33. Global KRAS Inhibitor Sales Share by Company (2021-2026) Table 34. Global KRAS Inhibitor Market Price by Company (2021-2026) & (USD/bottle) Table 35. Global KRAS Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global KRAS Inhibitor Major Company Production Sites and Headquarters Table 37. Global KRAS Inhibitor Company, Product Type & Application Table 38. Global KRAS Inhibitor Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global KRAS Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global KRAS Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global KRAS Inhibitor Sales by Region (2021-2026) & (k bottles) Table 43. Global KRAS Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 44. Global KRAS Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 45. Global KRAS Inhibitor Sales Market Share in Value by Region (2021-2026) Table 46. Global KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 47. Global KRAS Inhibitor Sales by Region (2027-2032) & (k bottles) Table 48. Global KRAS Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 49. Global KRAS Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 50. Global KRAS Inhibitor Sales Market Share in Value by Region (2027-2032) Table 51. Global KRAS Inhibitor Sales (k bottles), Value (US$ Million), Price (USD/bottle) and Gross Margin (2027-2032) Table 52. Global KRAS Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 54. Global KRAS Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 55. Global KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 56. Global KRAS Inhibitor Sales Market Share in Value by Application (2021-2026) Table 57. Global KRAS Inhibitor Price by Application (2021-2026) & (USD/bottle) Table 58. Global KRAS Inhibitor Sales by Application (2027-2032) & (k bottles) Table 59. Global KRAS Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 60. Global KRAS Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 61. Global KRAS Inhibitor Sales Market Share in Value by Application (2027-2032) Table 62. Global KRAS Inhibitor Price by Application (2027-2032) & (USD/bottle) Table 63. North America KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 64. North America KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 65. Europe KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 66. Europe KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 68. Asia-Pacific KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 70. Latin America KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa KRAS Inhibitor Sales by Application (2021-2026) & (k bottles) Table 72. Middle East and Africa KRAS Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 76. Amgen KRAS Inhibitor Product Portfolio Table 77. Amgen Recent Development Table 78. InventisBio/Chia Tai Tianqing Pharmaceutical Company Information Table 79. InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview Table 80. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 81. InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio Table 82. InventisBio/Chia Tai Tianqing Pharmaceutical Recent Development Table 83. Bristol Myers Squibb/Mirati Company Information Table 84. Bristol Myers Squibb/Mirati Business Overview Table 85. Bristol Myers Squibb/Mirati KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 86. Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio Table 87. Bristol Myers Squibb/Mirati Recent Development Table 88. Innovent Biologics/GenFleet Therapeutics Company Information Table 89. Innovent Biologics/GenFleet Therapeutics Business Overview Table 90. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 91. Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio Table 92. Innovent Biologics/GenFleet Therapeutics Recent Development Table 93. Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information Table 94. Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview Table 95. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales (k bottles), Revenue (US$ Million), Price (USD/bottle) and Gross Margin (2021-2026) Table 96. Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio Table 97. Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Development Table 98. North America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (k bottles): 2021 VS 2025 VS 2032 Table 99. North America KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 100. North America KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 101. North America KRAS Inhibitor Sales Forecast by Country (2027-2032) & (k bottles) Table 102. North America KRAS Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 103. North America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. North America KRAS Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 105. North America KRAS Inhibitor Market Share by Country (2021-2026) Table 106. North America KRAS Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. North America KRAS Inhibitor Market Share Forecast by Country (2027-2032) Table 108. Europe KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (k bottles): 2021 VS 2025 VS 2032 Table 109. Europe KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 110. Europe KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 111. Europe KRAS Inhibitor Sales Forecast by Country (2027-2032) & (k bottles) Table 112. Europe KRAS Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 113. Europe KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe KRAS Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe KRAS Inhibitor Market Share by Country (2021-2026) Table 116. Europe KRAS Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe KRAS Inhibitor Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (k bottles): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 120. Asia-Pacific KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 121. Asia-Pacific KRAS Inhibitor Sales Forecast by Country (2027-2032) & (k bottles) Table 122. Asia-Pacific KRAS Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific KRAS Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific KRAS Inhibitor Market Share by Country (2021-2026) Table 126. Asia-Pacific KRAS Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific KRAS Inhibitor Market Share Forecast by Country (2027-2032) Table 128. Latin America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (k bottles): 2021 VS 2025 VS 2032 Table 129. Latin America KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 130. Latin America KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 131. Latin America KRAS Inhibitor Sales Forecast by Country (2027-2032) & (k bottles) Table 132. Latin America KRAS Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 133. Latin America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America KRAS Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America KRAS Inhibitor Market Share by Country (2021-2026) Table 136. Latin America KRAS Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America KRAS Inhibitor Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (k bottles): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa KRAS Inhibitor Sales by Country (2021-2026) & (k bottles) Table 140. Middle East and Africa KRAS Inhibitor Sales Market Share by Country (2021-2026) Table 141. Middle East and Africa KRAS Inhibitor Sales Forecast by Country (2027-2032) & (k bottles) Table 142. Middle East and Africa KRAS Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa KRAS Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa KRAS Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East and Africa KRAS Inhibitor Market Share by Country (2021-2026) Table 146. Middle East and Africa KRAS Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa KRAS Inhibitor Market Share Forecast by Country (2027-2032) Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. KRAS Inhibitor Distributors List Table 151. KRAS Inhibitor Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. KRAS Inhibitor Image Figure 2. Global KRAS Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KRAS Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global KRAS Inhibitor Sales (2021-2032) & (k bottles) Figure 5. Lung Cancer Image Figure 6. Global Lung Cancer Sales YoY Growth (2021-2032) & (k bottles) Figure 7. Colorectal Cancer Image Figure 8. Global Colorectal Cancer Sales YoY Growth (2021-2032) & (k bottles) Figure 9. Pancreatic Cancer Image Figure 10. Global Pancreatic Cancer Sales YoY Growth (2021-2032) & (k bottles) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k bottles) Figure 13. Global KRAS Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global KRAS Inhibitor Market Share by Type 2025 VS 2032 Figure 15. North America KRAS Inhibitor Sales Market Share in Volume by Type in 2025 Figure 16. North America KRAS Inhibitor Sales Market Share in Value by Type in 2025 Figure 17. Europe KRAS Inhibitor Sales Market Share in Volume by Type in 2025 Figure 18. Europe KRAS Inhibitor Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific KRAS Inhibitor Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific KRAS Inhibitor Sales Market Share in Value by Type in 2025 Figure 21. Latin America KRAS Inhibitor Sales Market Share in Volume by Type in 2025 Figure 22. Latin America KRAS Inhibitor Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa KRAS Inhibitor Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa KRAS Inhibitor Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 KRAS Inhibitor Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinic Laboratories Image Figure 28. Global Clinic Laboratories Sales YoY Growth (2021-2032) & (k bottles) Figure 29. Hospitals Image Figure 30. Global Hospitals Sales YoY Growth (2021-2032) & (k bottles) Figure 31. Cancer Diagnostic Centres Image Figure 32. Global Cancer Diagnostic Centres Sales YoY Growth (2021-2032) & (k bottles) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (k bottles) Figure 35. Global KRAS Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global KRAS Inhibitor Market Share by Application 2025 VS 2032 Figure 37. North America KRAS Inhibitor Sales Market Share in Volume by Application in 2025 Figure 38. North America KRAS Inhibitor Sales Market Share in Value by Application in 2025 Figure 39. Europe KRAS Inhibitor Sales Market Share in Volume by Application in 2025 Figure 40. Europe KRAS Inhibitor Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific KRAS Inhibitor Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific KRAS Inhibitor Sales Market Share in Value by Application in 2025 Figure 43. Latin America KRAS Inhibitor Sales Market Share in Volume by Application in 2025 Figure 44. Latin America KRAS Inhibitor Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa KRAS Inhibitor Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa KRAS Inhibitor Sales Market Share in Value by Application in 2025 Figure 47. North America KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Figure 48. North America KRAS Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America KRAS Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America KRAS Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Figure 52. Europe KRAS Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe KRAS Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe KRAS Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Figure 56. Asia-Pacific KRAS Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific KRAS Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific KRAS Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Figure 60. Latin America KRAS Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America KRAS Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America KRAS Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa KRAS Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k bottles) Figure 64. Middle East and Africa KRAS Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa KRAS Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa KRAS Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. KRAS Inhibitor Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. KRAS Inhibitor Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others
Applications
  • Clinic Laboratories
  • Hospitals
  • Cancer Diagnostic Centres
  • Others
Companies covered
  • Amgen
  • InventisBio/Chia Tai Tianqing Pharmaceutical
  • Bristol Myers Squibb/Mirati
  • Innovent Biologics/GenFleet Therapeutics
  • Jacobio Pharma/Shanghai Allist Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global KRAS Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global KRAS Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 KRAS Inhibitor Market by Type
  6. 1.3.1 Lung Cancer
  7. 1.3.2 Colorectal Cancer
  8. 1.3.3 Pancreatic Cancer
  9. 1.3.4 Others
  10. 1.4 Global KRAS Inhibitor Market Size by Type
  11. 1.4.1 Global KRAS Inhibitor Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global KRAS Inhibitor Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global KRAS Inhibitor Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America KRAS Inhibitor Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe KRAS Inhibitor Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific KRAS Inhibitor Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America KRAS Inhibitor Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa KRAS Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 KRAS Inhibitor Industry Trends
  2. 2.2 KRAS Inhibitor Industry Drivers
  3. 2.3 KRAS Inhibitor Industry Opportunities and Challenges
  4. 2.4 KRAS Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by KRAS Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by KRAS Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by KRAS Inhibitor Price (2021-2026)
  4. 3.4 Global KRAS Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global KRAS Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global KRAS Inhibitor Company, Product Type & Application
  7. 3.7 Global KRAS Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global KRAS Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 KRAS Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 KRAS Inhibitor Tier 1, Tier 2, and Tier 3
4 KRAS Inhibitor Regional Status and Outlook
  1. 4.1 Global KRAS Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global KRAS Inhibitor Historic Market Size by Region
  3. 4.2.1 Global KRAS Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global KRAS Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global KRAS Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global KRAS Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global KRAS Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global KRAS Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global KRAS Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 KRAS Inhibitor by Application
  1. 5.1 KRAS Inhibitor Market by Application
  2. 5.1.1 Clinic Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Cancer Diagnostic Centres
  5. 5.1.4 Others
  6. 5.2 Global KRAS Inhibitor Market Size by Application
  7. 5.2.1 Global KRAS Inhibitor Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global KRAS Inhibitor Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global KRAS Inhibitor Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America KRAS Inhibitor Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe KRAS Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific KRAS Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America KRAS Inhibitor Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa KRAS Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Amgen
  2. 6.1.1 Amgen Company Information
  3. 6.1.2 Amgen Business Overview
  4. 6.1.3 Amgen KRAS Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Amgen KRAS Inhibitor Product Portfolio
  6. 6.1.5 Amgen Recent Developments
  7. 6.2 InventisBio/Chia Tai Tianqing Pharmaceutical
  8. 6.2.1 InventisBio/Chia Tai Tianqing Pharmaceutical Company Information
  9. 6.2.2 InventisBio/Chia Tai Tianqing Pharmaceutical Business Overview
  10. 6.2.3 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 InventisBio/Chia Tai Tianqing Pharmaceutical KRAS Inhibitor Product Portfolio
  12. 6.2.5 InventisBio/Chia Tai Tianqing Pharmaceutical Recent Developments
  13. 6.3 Bristol Myers Squibb/Mirati
  14. 6.3.1 Bristol Myers Squibb/Mirati Company Information
  15. 6.3.2 Bristol Myers Squibb/Mirati Business Overview
  16. 6.3.3 Bristol Myers Squibb/Mirati KRAS Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bristol Myers Squibb/Mirati KRAS Inhibitor Product Portfolio
  18. 6.3.5 Bristol Myers Squibb/Mirati Recent Developments
  19. 6.4 Innovent Biologics/GenFleet Therapeutics
  20. 6.4.1 Innovent Biologics/GenFleet Therapeutics Company Information
  21. 6.4.2 Innovent Biologics/GenFleet Therapeutics Business Overview
  22. 6.4.3 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Innovent Biologics/GenFleet Therapeutics KRAS Inhibitor Product Portfolio
  24. 6.4.5 Innovent Biologics/GenFleet Therapeutics Recent Developments
  25. 6.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals
  26. 6.5.1 Jacobio Pharma/Shanghai Allist Pharmaceuticals Company Information
  27. 6.5.2 Jacobio Pharma/Shanghai Allist Pharmaceuticals Business Overview
  28. 6.5.3 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Jacobio Pharma/Shanghai Allist Pharmaceuticals KRAS Inhibitor Product Portfolio
  30. 6.5.5 Jacobio Pharma/Shanghai Allist Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America KRAS Inhibitor Sales by Country
  2. 7.1.1 North America KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America KRAS Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America KRAS Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America KRAS Inhibitor Market Size by Country
  6. 7.2.1 North America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America KRAS Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America KRAS Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe KRAS Inhibitor Sales by Country
  2. 8.1.1 Europe KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe KRAS Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe KRAS Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe KRAS Inhibitor Market Size by Country
  6. 8.2.1 Europe KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe KRAS Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe KRAS Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific KRAS Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific KRAS Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific KRAS Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific KRAS Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific KRAS Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific KRAS Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America KRAS Inhibitor Sales by Country
  2. 10.1.1 South America KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America KRAS Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America KRAS Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America KRAS Inhibitor Market Size by Country
  6. 10.2.1 South America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America KRAS Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America KRAS Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa KRAS Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa KRAS Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa KRAS Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa KRAS Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa KRAS Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa KRAS Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 KRAS Inhibitor Value Chain Analysis
  2. 12.1.1 KRAS Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 KRAS Inhibitor Production Mode & Process
  7. 12.2 KRAS Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 KRAS Inhibitor Distributors
  10. 12.2.3 KRAS Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst